Retractable Technologies Q2 net sales fall to $7.2 million from $10.4 million
Retractable Technologies reported second-quarter 2026 net sales of $7.2 million, down from $10.4 million a year earlier, with an operating loss of $5.1 million in both periods. The company attributed the sales decline mainly to the timing of EasyPoint needle orders and to unusually high flu season unit sales in the second quarter of 2025. Second-quarter net income of $2.8 million was driven by a $6.4 million gain on the sale of equity securities, while the first half shows a net loss of $1.4 million and a wider operating loss of $11.3 million.
Key points
- Q2 2026 net sales were $7.2 million versus $10.4 million in Q2 2025; operating loss was $5.1 million in both periods.
- First-half 2026 net sales were $14.4 million versus $18.7 million; operating loss widened to $11.3 million from $9.8 million.
- Q2 2026 net income of $2.8 million included a $6.4 million realized gain on sale of equity; first-half net loss was $1.4 million.
- A reduction in force in April 2026 is expected to produce cost savings in future periods.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.